In Brief: Ocurest Labs
This article was originally published in The Tan Sheet
Executive Summary
Ocurest Labs: Ocurest medicated eye drops holds a 3.2% share of the category unit sales in March, up from 2.1% in February and 1.7% in January, based on data from Information Resources, Inc., the firm says. The product, in redness relief and lubricating formulas, had first quarter sales of $448,000. The Palm Beach, Fla.-based company attributes its share gain to national advertising that began in late 1996 following a launch earlier last year. The product is manufactured by Bausch & Lomb. Ocurest plans to introduce an allergy relief formula early next year under a licensing agreement with Ciba/Novartis ("The Tan Sheet" March 24, In Brief). The medicated eye drops market is led by Pfizer's Visine with a 45% share, followed by Ross Labs' Clear Eyes and Murine, with a 19% share and Bausch & Lomb (Sensitive Eyes, Moisture Drops and Opcon), with 11%..
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning